New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)
作者： J. Cotter
DOI: 10.1503/CMAJ.050456
关键词:
摘要: Reason for posting: Coxibs, the class of NSAIDs that selectively inhibit cyclooxygenase 2 (COX-2), were designed to reduce joint pain and inflammation without causing gastric epithelial adverse effects typical nonselective NSAIDs. Rofecoxib (Vioxx) was withdrawn from market in September
core.ac.uk
sci-hub.se 参考文章(2)
Nancy A. Nussmeier, Andrew A. Whelton, Mark T. Brown, Richard M. Langford, Andreas Hoeft, Joel L. Parlow, Steven W. Boyce, Kenneth M. Verburg, Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery The New England Journal of Medicine. ,vol. 352, pp. 1081- 1091 ,(2005) , 10.1056/NEJMOA050330
Scott D Solomon, John JV McMurray, Marc A Pfeffer, Janet Wittes, Robert Fowler, Peter Finn, William F Anderson, Ann Zauber, Ernest Hawk, Monica Bertagnolli, None, Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention The New England Journal of Medicine. ,vol. 352, pp. 1071- 1080 ,(2005) , 10.1056/NEJMOA050405